Photo of Stephen E.F. Spurgeon, MD

Stephen E.F. Spurgeon MD

Dr. Spurgeon received his M.D. from Jefferson Medical College at Thomas Jefferson University in Philadelphia. He continued his training in internal medicine at OHSU, where he also served as chief resident. Subsequently he completed his fellowship in hematology and medical oncology at OHSU where he conducted clinical and laboratory research in lymphoid cancers. He joined the OHSU faculty at the Center for Hematologic Malignancies in July 2009 as an assistant professor.

When he is not working, Dr. Spurgeon enjoys time with his wife and two small children. He is an avid sports fan, loves good food, and enjoys the outdoors.

Read more


  • M.D., Jefferson Medical College at Thomas Jefferson University, Philadelphia Pennsylvania 0 2002
  • Residency:

    • 2002-2005, residency: Oregon Health & Science University, Portland, Oregon
  • Fellowship:

    • 2006-2009, fellowship: Oregon Health & Science University, Portland, Oregon
  • Certifications:

    • American Board of Internal Medicine (internal medicine), 2005

Memberships and associations

  • American Society of Oncology


  • "Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma." Haematologica In: , Vol. 102, No. 7, 26.06.2017, p. e261-e265.
  • "Obinutuzumab is effective in chronic lymphocytic leukemia and rheumatoid arthritis after rituximab failure : A case report." American Journal of Case Reports  In: , Vol. 18, 10.05.2017, p. 516-519.
  • "Identification of targeted therapies for rare adult mature T-cell leukemia using functional ex vivo screening of primary patient samples." American Journal of Hematology  In: , Vol. 92, No. 5, 01.05.2017, p. E64-E66.
  • "CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation." Leukemia Research In: , Vol. 53, 01.02.2017, p. 39-49.
  • "Concurrent STAT3, DNMT3A, and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential." American Journal of Hematology In: , Vol. 92, No. 1, 01.01.2017, p. E6-E8.
  • "Recommendations for clinical trial development in mantle cell lymphoma." Journal of the National Cancer Institute In: , Vol. 109, No. 1, djw263, 2017.
  • "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia." Science Translational Medicine In: , Vol. 8, No. 354, 354ra114, 31.08.2016.
  • "Phase 2 study of idelalisib and entospletinib : Pneumonitis limits combination therapy in relapsed refractory CLL and NHL." Blood In: , Vol. 127, No. 20, 19.05.2016, p. 2411-2415.
  • "Postibrutinib outcomes in patients with mantle cell lymphoma." Blood In: , Vol. 127, No. 12, 24.03.2016, p. 1559-1563.
  • "Cardiac non-Hodgkin's lymphoma : Clinical characteristics and trends in survival." European Journal of Haematology In: , 2016.
  • "Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia." British Journal of Haematology In: , 2016.
  • "MYD88 mutation analysis of a rare composite chronic lymphocyte leukemia and lymphoplasmacytic lymphoma by flow cytometry cell sorting." Annals of Hematology  In: , Vol. 94, No. 11, 22.11.2015, p. 1941-1944.
  • "Cyclin-dependent kinase inhibitor P1446A induces apoptosis in a JNK/p38 MAPK-dependent manner in chronic lymphocytic leukemia B-cells." PLoS One In: , Vol. 10, No. 11, e0143685, 01.11.2015.
  • "Long-term follow-up of MCL patients treated with single-agent ibrutinib : Updated safety and efficacy results." Blood  In: , Vol. 126, No. 6, 06.08.2015, p. 739-745.
  • "Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome." Leukemia Research Reports  In: , Vol. 4, No. 1, 01.01.2015, p. 8-11.
  • "Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients." British Journal of Haematology In: , Vol. 168, No. 1, 01.01.2015, p. 38-45.
  • "Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma." Oncotarget In: , Vol. 6, No. 22, 2015, p. 18921-18932.
  • "Ibrutinib in mantle cell lymphoma patients : Glass half full? Evidence and opinion." Therapeutic Advances in Hematology In: , Vol. 6, No. 5, 2015, p. 242-252.
  • "Aberrations of MYC are a common event in B-cell prolymphocytic leukemia." American Journal of Clinical Pathology  In: , Vol. 142, No. 3, 01.09.2014, p. 347-354.
  • "Chronic lymphocytic leukemia with a FGFR3 translocation : Case report and literature review of an uncommon cytogenetic event." Cancer genetics In: , Vol. 207, No. 7-8, 01.07.2014, p. 340-343.
  • "A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)." Blood In: , Vol. 123, No. 22, 29.05.2014, p. 3398-3405.
  • "Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia." Blood In: , Vol. 123, No. 22, 29.05.2014, p. 3390-3397.
  • "Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma." Blood In: , Vol. 123, No. 22, 29.05.2014, p. 3406-3413.
  • "A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia." Blood In: , Vol. 123, No. 9, 27.02.2014, p. 1302-1308.
  • "A potential therapeutic strategy for chronic lymphocytic leukemia by combining idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor." Oncotarget In: , Vol. 5, No. 4, 2014, p. 908-915.
  • "Improved survival in hairy cell leukaemia over three decades : A SEER database analysis of prognostic factors." British Journal of Haematology In: , Vol. 163, No. 3, 11.2013, p. 407-409.
  • "CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway." Leukemia In: , Vol. 27, No. 10, 10.2013, p. 2094-2096.
  • "The selective syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemias." Journal of Pharmacology and Experimental Therapeutics In: , Vol. 344, No. 2, 02.2013, p. 378-387.
  • "Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening." Cancer Research In: , Vol. 73, No. 1, 01.01.2013, p. 285-296.
  • "Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma." New England Journal of Medicine In: , Vol. 369, No. 6, 2013, p. 507-516.

Additional information

Edit profile